Terlipressin
FDA-approved terlipressin for HRS (hepatorenal syndrome, kidney failure linked to liver disease).
What it's for
FDA-approved terlipressin for HRS (hepatorenal syndrome, kidney failure linked to liver disease).
What it's for
Terlipressin is a synthetic vasopressin analog that acts primarily via V1 receptors (lock-and-key landing spots on cells) after conversion to lysine-vasopressin. It is approved to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function, used in carefully selected hospitalized patients.
What it does for the body
It is approved to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function, used in carefully selected hospitalized patients. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Splanchnic blood-vessel tightening reduces portal pressure and redistributes blood flow, improving renal perfusion in HRS (hepatorenal syndrome, kidney failure linked to liver disease) pathophysiology. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Terlipressin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Terlipressin — FDA.gov search
- ClinicalTrials.gov search: Terlipressin — U.S. clinical trials registry
- Drugs@FDA search: Terlipressin — FDA drug database (if approved)
- PubMed search: Terlipressin — NCBI PubMed
- PubMed Central search: Terlipressin — NCBI PMC